Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.55 |
| ▸ | TNF | P01375 | 5/20 | 0.55 |
| ▸ | SRC | P12931 | 4/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.54 |
| ▸ | RAF1 | P04049 | 2/20 | 0.54 |
| ▸ | LYN | P07948 | 2/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.49 |
| ▸ | HCK | P08631 | 5/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.47 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.47 |
| ▸ | CIT | O14578 | 1/20 | 0.46 |
| ▸ | MUSK | O15146 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | STK10 | O94804 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088021 | 0.82 | ABL1 (0.63) | MAPK14TNFSRCABL1RAF1 | |
| SCHEMBL4095048 | 0.82 | ABL1 (0.75) | MAPK14TNFSRCABL1RAF1 | |
| SCHEMBL4092352 | 0.81 | SRC (0.58) | MAPK14TNFSRCABL1RAF1 | |
| SCHEMBL4091363 | 0.81 | PTK2 (0.61) | MAPK14TNFSRCABL1RAF1 | |
| SCHEMBL4096411 | 0.81 | SRC (0.54) | MAPK14TNFSRCABL1RAF1 | |
| SCHEMBL5989884 | 0.81 | SRC (0.56) | MAPK14TNFSRCABL1RAF1 | |
| SCHEMBL4085911 | 0.81 | MAPK14 (0.53) | MAPK14TNFSRCABL1RAF1 | |
| SCHEMBL4095787 | 0.81 | MAPK14 (0.62) | MAPK14TNFSRCABL1RAF1 | |
| SCHEMBL4085915 | 0.80 | SRC (0.58) | MAPK14TNFSRCABL1RAF1 | |
| SCHEMBL4088539 | 0.80 | MAPK14 (0.57) | MAPK14TNFSRCABL1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123516-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2007-05-31 | — | — | US | claimed |
| US-20030220336-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123516-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | MAPK14 44/4885TNF 707/4885SRC 1828/4885 |
| US-20030220336-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | MAPK14 44/4885TNF 707/4885SRC 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.